– USA, MA – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical-stage pharmaceutical company, today announced the appointment of current Board member Dr. Brian Pereira (M.D.) as Chairman of the Board of Directors, effective immediately, replacing Dr. Martin Edwards who resigned from the Board.
“We are pleased that Brian has agreed to take the Chairman role at this critical time,” said CEO, Andrew Crockett. “Brian’s long experience in late-stage drug development and commercialization will be particularly valuable in his new role as KalVista continues to grow into a pre-commercial company focused on advancing sebetralstat as the first oral on-demand therapy for the treatment of HAE attacks. We also thank Martin, who was one of the founding investors in KalVista, for his years of loyal service and friendship to the company, and we wish him well in his future endeavors.”
About Brian J.G. Pereira
Dr. Pereira has been a member of the KalVista Board of Directors since 2019 and is currently President & CEO of Visterra, Inc., a subsidiary of Otsuka Pharmaceuticals focused on biologics research and clinical development of therapies for patients with immune-mediated and other hard-to-treat diseases. Dr. Pereira previously served as President and CEO of AMAG Pharmaceuticals. He raised four financing rounds at increasing valuations and built the clinical development, manufacturing, supply chain and commercial infrastructure for Feraheme. Before AMAG Pharmaceuticals, he held senior roles at Tufts Medical Center, including President and CEO of a Tufts Medical Center Physician Organization and interim COO. He is an Adjunct Professor of Medicine at Tufts University School of Medicine and has authored over 200 published scientific articles.
Dr. Pereira received his medical degree (MBBS) from St. John’s Medical College, MD (Medicine), and DM (Nephrology) from the Post Graduate Institute, and MBA from Kellogg School of Management at Northwestern University.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing oral, small-molecule protease inhibitors for diseases with significant unmet needs. KalVista has developed a proprietary portfolio of novel, small-molecule plasma kallikrein inhibitors initially targeting hereditary angioedema and diabetic macular edema. KalVista is developing sebetralstat as an oral on-demand therapy for HAE attacks and is enrolling in Phase 3 KONFIDENT clinical trial. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment for people living with HAE. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.
For more information:https://www.kalvista.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.